BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shivaji UN, Jeffery L, Gui X, Smith SCL, Ahmad OF, Akbar A, Ghosh S, Iacucci M. Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therap Adv Gastroenterol 2019;12:1756284819884196. [PMID: 31723355 DOI: 10.1177/1756284819884196] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Picardo SL, Doi J, Hansen AR. Structure and Optimization of Checkpoint Inhibitors. Cancers (Basel) 2019;12:E38. [PMID: 31877721 DOI: 10.3390/cancers12010038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
2 Egg D, Rump IC, Mitsuiki N, Rojas-Restrepo J, Maccari ME, Schwab C, Gabrysch A, Warnatz K, Goldacker S, Patiño V, Wolff D, Okada S, Hayakawa S, Shikama Y, Kanda K, Imai K, Sotomatsu M, Kuwashima M, Kamiya T, Morio T, Matsumoto K, Mori T, Yoshimoto Y, Dybedal I, Kanariou M, Kucuk ZY, Chapdelaine H, Petruzelkova L, Lorenz HM, Sullivan KE, Heimall J, Moutschen M, Litzman J, Recher M, Albert MH, Hauck F, Seneviratne S, Pachlopnik Schmid J, Kolios A, Unglik G, Klemann C, Snapper S, Giulino-Roth L, Svaton M, Platt CD, Hambleton S, Neth O, Gosse G, Reinsch S, Holzinger D, Kim YJ, Bakhtiar S, Atschekzei F, Schmidt R, Sogkas G, Chandrakasan S, Rae W, Derfalvi B, Marquart HV, Ozen A, Kiykim A, Karakoc-Aydiner E, Králíčková P, de Bree G, Kiritsi D, Seidel MG, Kobbe R, Dantzer J, Alsina L, Armangue T, Lougaris V, Agyeman P, Nyström S, Buchbinder D, Arkwright PD, Grimbacher B. Therapeutic options for CTLA-4 insufficiency. J Allergy Clin Immunol 2021:S0091-6749(21)00891-5. [PMID: 34111452 DOI: 10.1016/j.jaci.2021.04.039] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Griewing LM, Schweizer C, Schubert P, Rutzner S, Eckstein M, Frey B, Haderlein M, Weissmann T, Semrau S, Gostian AO, Müller SK, Traxdorf M, Iro H, Zhou JG, Gaipl US, Fietkau R, Hecht M. Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors. BMC Cancer 2021;21:314. [PMID: 33761922 DOI: 10.1186/s12885-021-08006-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Richter MD, Hughes GC, Chung SH, Ezeanuna M, Singh N, Thompson JA. Immunologic adverse events from immune checkpoint therapy. Best Practice & Research Clinical Rheumatology 2020;34:101511. [DOI: 10.1016/j.berh.2020.101511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Nakashima K, Demura Y, Oi M, Tabata M, Tada T, Shiozaki K, Akai M, Ishizuka T. Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab. Intern Med 2020;59:3055-9. [PMID: 32727989 DOI: 10.2169/internalmedicine.5216-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jiang G, Shi L, Zheng X, Zhang X, Wu K, Liu B, Yan P, Liang X, Yu T, Wang Y, Cai X. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma. Aging (Albany NY) 2020;12:11466-84. [PMID: 32579541 DOI: 10.18632/aging.103231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Ralli M, Botticelli A, Visconti IC, Angeletti D, Fiore M, Marchetti P, Lambiase A, de Vincentiis M, Greco A. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. J Immunol Res 2020;2020:9235638. [PMID: 32671117 DOI: 10.1155/2020/9235638] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
8 Wang A, Xu Y, Fei Y, Wang M. The role of immunosuppressive agents in the management of severe and refractory immune-related adverse events. Asia Pac J Clin Oncol 2020;16:201-10. [PMID: 32212243 DOI: 10.1111/ajco.13332] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Sun H, Zhang Q, Li J, Peng S, Wang X, Cai R. Near-infrared photoactivated nanomedicines for photothermal synergistic cancer therapy. Nano Today 2021;37:101073. [DOI: 10.1016/j.nantod.2020.101073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Farha N, Alkhayyat M, Lindsey A, Mansoor E, Saleh MA. Immune Checkpoint Inhibitor Induced Colitis: A Nationwide Population-Based Study. Clin Res Hepatol Gastroenterol 2021;:101778. [PMID: 34332139 DOI: 10.1016/j.clinre.2021.101778] [Reference Citation Analysis]
11 Li M, Liang M, Lan T, Wu X, Xie W, Wang T, Chen Z, Shen S, Peng B. Four Immune-Related Long Non-coding RNAs for Prognosis Prediction in Patients With Hepatocellular Carcinoma. Front Mol Biosci 2020;7:566491. [PMID: 33364253 DOI: 10.3389/fmolb.2020.566491] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Cho YA, Han JM, Kang SY, Kim DC, Youn YJ, Choi KH, Gwak HS. Analysis of Risk Factors for Hepatotoxicity Induced by Immune Checkpoint Inhibitors. J Immunother 2021;44:16-21. [PMID: 33290362 DOI: 10.1097/CJI.0000000000000347] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 O'Reilly M, Mellotte G, Ryan B, O'Connor A. Gastrointestinal side effects of cancer treatments. Ther Adv Chronic Dis 2020;11:2040622320970354. [PMID: 33294145 DOI: 10.1177/2040622320970354] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
14 Ruggiero R, Fraenza F, Scavone C, di Mauro G, Piscitelli R, Mascolo A, Ferrajolo C, Rafaniello C, Sportiello L, Rossi F, Capuano A. Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. Front Pharmacol 2020;11:830. [PMID: 32581796 DOI: 10.3389/fphar.2020.00830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Mascolo A, Scavone C, Ferrajolo C, Rafaniello C, Danesi R, Del Re M, Russo A, Coscioni E, Rossi F, Alfano R, Capuano A. Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance. Drug Saf 2021;44:957-71. [PMID: 34145536 DOI: 10.1007/s40264-021-01086-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ping Y, Li F, Nan S, Zhang D, Shi X, Shan J, Zhang Y. Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv. Front Cell Dev Biol 2020;8:803. [PMID: 32974346 DOI: 10.3389/fcell.2020.00803] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
17 Asahi Y, Kamiyama T, Kakisaka T, Orimo T, Shimada S, Nagatsu A, Sakamoto Y, Ishikawa T, Kamachi H, Mitsuhashi T, Takeuchi S, Dosaka-Akita H, Taketomi A. Hepatectomy and immune checkpoint inhibitor treatment for liver metastasis originating from non-cutaneous melanoma: a report of three cases. Int Cancer Conf J 2021;10:274-9. [PMID: 34567937 DOI: 10.1007/s13691-021-00495-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Sleiman J, Wei W, Shah R, Faisal MS, Philpott J, Funchain P. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study. J Immunother Cancer 2021;9:e002567. [PMID: 34158318 DOI: 10.1136/jitc-2021-002567] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Maslov DV, Tawagi K, Kc M, Simenson V, Yuan H, Parent C, Bamnolker A, Goel R, Blake Z, Matrana MR, Johnson DH. Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer. J Immunother Cancer 2021;9:e002261. [PMID: 34226279 DOI: 10.1136/jitc-2020-002261] [Reference Citation Analysis]
20 Fernandes DC, Jervoise N Andreyev H. Chronic diarrhoea in an oncology patient - Clinical assessment and decision making. Best Pract Res Clin Gastroenterol 2020;48-49:101708. [PMID: 33317791 DOI: 10.1016/j.bpg.2020.101708] [Reference Citation Analysis]
21 Yao J, Li M, Zhang H, Ge Y, Weygant N, An G. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. Int Immunopharmacol. 2020;87:106770. [PMID: 32702598 DOI: 10.1016/j.intimp.2020.106770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]